NovaBridge Biosciences (NBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '24: -12.4M Q4 '24: -13.4M Q3 '25: -9M Q4 '25: -72.9M Q3 '24 Q4 '24 Q3 '25 Q4 '25

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -20.5M Q4 '24: -10.8M Q3 '25: -6.8M Q4 '25: -30.8M Q3 '24 Q4 '24 Q3 '25 Q4 '25

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '24: 8.4M Q4 '24: -10.9M Q3 '25: 1.8M Q4 '25: -14.6M Q3 '24 Q4 '24 Q3 '25 Q4 '25

Free Cash Flow Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '24: 8.4M Q4 '24: -11M Q3 '25: 1.8M Q4 '25: -14.6M Q3 '24 Q4 '24 Q3 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.